Università degli Studi di Perugia

Vai al contenuto principale
Menu

TITOLO DEL BREVETTO

Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease

 

STATO

Disponibile

 

NUMERO DOMANDA DI PRIORITA’

EP 13305034.4 - a nome dell'Institut Pasteur

 

DATA DI PRIORITÀ

14/01/2013

 

FASE

EUROPA, esteso a PCT

 

DIPARTIMENTO

Dipartimento di Medicina Sperimentale

 

AUTORI

Luigina Romani, Antonella De Luca, Silvia Bozza, Jean Paul Latgé; Thierry Fontaine, F. van de Veerdonck, L. Joosten, M. Gresnigt, M. Netea

 

CO-TITOLARI

INSTITUT PASTEUR (46%) - Università degli Studi di Perugia (25%) - RADBOUD UNIVERSITY NIJMEGEN (29%)  

 

DESCRIZIONE

A first object of the invention is galactosaminogalactan comprising [alpha]1-4 linked galactose, [alpha]1-4 linked N-acetylgalactosamine, and optionally [alpha]1-4 linked galactosamine, for use in the treatment of at least one inflammatory disease. Another object of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising [alpha]1-4 linked galactose, [alpha]1-4 linked N-acetylgalactosamine, and optionally [alpha]1-4 linked galactosamine, as defined herein, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1RA, and optionally a pharmaceutically acceptable carrier.

 

CONTATTO

ufficio.ilo@unipg.it

Info pagina

Referente di sezione

Prof. Loris Lino Maria Nadotti
(Delegato per il settore Brevetti, innovazione e trasferimento tecnologico)

Ultimo aggiornamento
8/3/2017

Torna su
×